Clinical Trials Sponsored by ADIR, a Servier Group company

Total 110 results

Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Recruiting

Immuno-positron Emission Tomography Study of 89Zr-S095012 in Patients With Advanced Solid Tumours

Advanced Solid Tumor

Netherlands
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Terminated

Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer (COLSTAR)

Metastatic Colorectal Cancer

Denmark, Japan, Belgium, Finland, Hungary, United States
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.

Acute Myeloid Leukaemia

France, United States, Australia
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS) | Acute Myeloid Leukaemia (AML)

United States, Australia, France, Spain
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Vascular Function and Biomarker Assessments in Healthy Volunteers and in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Germany
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Austria, France, Hungary, United Kingdom, Italy, Germany, Spain
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Active, not recruiting

S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers

Solid Tumor

United States, Canada
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Active, not recruiting

A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Leukemia Who Have Been Previously Administered With UCART19

Advanced Lymphoid Leukemia

United States, United Kingdom, Japan, France, Spain
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Terminated

Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.

Autism Spectrum Disorder (ASD)

Spain, United States, Hungary, Poland, Australia, United Kingdom, Brazil, Czechia, France, Italy, Portugal, Slovakia
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Withdrawn

S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC

Esophageal Squamous Cell Carcinoma
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Terminated

Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder

Autism Spectrum Disorder (ASD)

Spain, Hungary, Poland, Brazil, France, Italy, Portugal, United Kingdom, Germany, Netherlands
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia (PALL)

Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic Leukemia

United States, France, Spain, United Kingdom
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy (TASCO1)

Metastatic Colorectal Cancer

United Kingdom, Spain, Germany, Poland, Australia, Belgium, Brazil, Denmark, France, Italy, Netherlands, Russian Federation
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia (CALM)

B-cell Acute Lymphoblastic Leukemia

United States, United Kingdom, Japan, France
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Post Marketing Surveillance Study for ONIVYDE® in South Korea

Metastatic Pancreatic Cancer

Korea, Republic of
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Efficacy and Safety Trial With S 44819 After Recent Ischemic Cerebral Event

Post Stroke Recovery

Belgium, Italy, United Kingdom, Korea, Republic of, Czechia, Poland, Brazil, Australia, Hungary, Canada, France, Germany, Netherlands, Spain, Sweden
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Safety of Single Intravenous Administration of S95010 in Human Healthy Volunteers

Cardiovascular Diseases

Belgium
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma

Chronic Lymphocytic Leukaemia (CLL) | Multiple Myeloma (MM) | B-Cell Non-Hodgkin Lymphoma (NHL)

France, Australia, Germany, Korea, Republic of, United Kingdom, Hungary, Poland, Singapore
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS) | Acute Myeloid Leukaemia (AML)

France, Australia
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Recruiting

Calaspargase Pegol in Adults With ALL

Acute Lymphoblastic Leukemia

United States
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Recruiting

Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia

Acute Myeloid Leukemia

France, Korea, Republic of, Spain, United Kingdom, Hungary, Poland
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia

Relapsed or Refractory Multiple Myeloma | Relapsed or Refractory Acute Myeloid Leukemia | Relapsed or Refractory Non-Hodgkin Lymphoma | Relapsed or Refractory Chronic Lymphocytic Leukemia

United Kingdom, Spain, France, Australia
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Active, not recruiting

Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy. (SOLSTICE)

Metastatic Colorectal Cancer

United Kingdom, Lithuania, France, Sweden, Australia, Latvia, Spain, Poland, Argentina, Austria, Brazil, Bulgaria, Czechia, Denmark, Estonia, Germany, Hungary, Ireland, Italy, Netherlands, Portugal, Romania, Russian Federation, Slovakia, Ukrai...
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Terminated

Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia

Hypertension | Dyslipidemias

Georgia, Russian Federation, Ukraine
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Active, not recruiting

Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia

Acute Myeloid Leukaemia

United States, Australia, France, Spain
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Efficacy and Safety of S95011 in Primary Sjögren's Syndrome Patients

Primary Sjögren's Syndrome

United States, France, United Kingdom, Australia, Germany, Hungary, Spain
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies

Metastatic Colorectal Cancer

Russian Federation
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic). (PRECONNECT)

Metastatic Colorectal Cancer

Turkey, Poland, Brazil, France, Ireland, Italy, Portugal, Romania, Ukraine, Bulgaria, Australia, Belgium, Croatia, Panama, Slovakia, Slovenia
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

S 81694 Plus Paclitaxel in Metastatic Breast Cancer

Metastatic Breast Cancer | Metastatic Triple Negative Breast Cancer

Japan, Belgium, France, Netherlands
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer

Metastatic Pancreatic Cancer

Japan
Institut de Recherches Internationales Servier
ADIR, a Servier Group company; Les Laboratoires Servier (L.L.S), Russia

Completed

A Roll-over Study to Provide Continued Treatment With Lyophilized Pegaspargase (S95014) in Pediatric Patients With Acute Lymphoblastic Leukemia (ALL) (ALL)

Acute Lymphoblastic Leukemia

Russian Federation
Institut de Recherches Internationales Servier
ADIR, a Servier Group company; Les Laboratoires Servier (L.L.S), Russia

Completed

A Study Comparing the Blood Levels of Both Pegaspargase (S95014) Formulations (Liquid vs Lyophilized) in the Treatment of Paediatric Patients With Acute Lymphoblastic Leukemia (ALL) (ALL)

Acute Lymphoblastic Leukemia

Russian Federation
Institut de Recherches Internationales Servier
Kyowa Kirin Co., Ltd.; ADIR, a Servier Group company

Completed

A Clinical Study of SHP674 (Pegaspargase) in Participants With Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Japan
Opera CRO, a TIGERMED Group Company

Completed

Validation of Romanian Version of Radner Reading Charts

Visual Acuity

Romania
Opera CRO, a TIGERMED Group Company

Completed

Clinical Study to Evaluate Antibody and Cell Mediated Immunity of A/H1N1 Influenza Vaccine in Healthy Subjects

Influenza

Italy
Opera CRO, a TIGERMED Group Company

Completed

Performance and Tolerability of a New Medical Device Gel, a Randomized, Open Label, Parallel-group, Multicentre Study

Tooth Disease
Italfarmaco
Opera CRO, a TIGERMED Group Company

Completed

Clinical Trial Study To Evaluate The Performance And Safety Of Ainara®

Vaginal Disease

Romania
Italfarmaco
Opera CRO, a TIGERMED Group Company

Completed

Open Non-Comparative Study To Evaluate Administration Of a New Nutraceutical

Sleep Disorder

Romania
Italfarmaco
Opera CRO, a TIGERMED Group Company

Completed

Open Non-Comparative Clinical Trial Study To Evaluate The Performance And Safety Of Ainara®

Vaginal Disease

Romania
Italfarmaco
Opera CRO, a TIGERMED Group Company

Not yet recruiting

Prevalence And Burden Of Nausea And Vomiting In Pregnant Women (PURITY)

Nausea Gravidarum | Vomiting of Pregnancy

Italy
Italfarmaco
Opera CRO, a TIGERMED Group Company

Completed

Post Marketing Follow Up Study To Evaluate Performance Safety Quality of Menopausal Transition Women Treated With Ainara

Vaginal Disease

Romania
Mesoestetic Pharma Group S.L.
Opera CRO, a TIGERMED Group Company

Completed

Pilot Trial to Assess the Performance and Tolerance of mRDX-02-17 Dermal Filler in the Facial Rejuvenation

Facial Rejuvenation

Romania
Giellepi S.p.A
Opera CRO, a TIGERMED Group Company

Not yet recruiting

Randomised, Double-blind, Placebo-controlled to Assess the Efficacy and Safety of the Food Supplement Microsmin® Plus

Haemorrhoids

Romania
SIFI SpA
Opera CRO, a TIGERMED Group Company

Completed

The Visual Performances of a Progressive Multifocal Intraocular Lens With Extended Depth of Focus

Cataract | Presbyopia

Italy
SIFI SpA
Opera CRO, a TIGERMED Group Company

Terminated

Non-Inferiority Study Comparing MINI WELL READY® and FineVision® in Patients With Cataract Surgery

Cataract | Presbyopia

France
MDM S.p.A.
Opera CRO, a TIGERMED Group Company

Completed

Non-Comparative Study to Assess the Efficacy and Safety of the New Food Supplement FaseMETS

Metabolic Syndrome

Romania
Citieffe S.r.l
Opera CRO, a TIGERMED Group Company

Unknown

Observational Retrospective and Prospective Study on the Treatment of Femoral Fractures With EBA2

Femoral Fractures

Italy
Effik SA
Opera CRO, a TIGERMED Group Company

Not yet recruiting

Prevalence and Burden of Nausea and Vomiting in Pregnant Women in Switzerland: Survey Purity 2022

Nausea | Vomiting of Pregnancy
BMG Pharma
Opera CRO, a TIGERMED Group Company

Recruiting

Evaluation of Safety and Performance of Ialuxid Gel in Treatment of Acne Vulgaris, Impetigo and Folliculitis

Acne Vulgaris | Folliculitis | Impetigo

Romania
Biokosmes Srl
Opera CRO, a TIGERMED Group Company

Completed

Open-label Trial Evaluating Four Oral Hygiene Regimens Using a Manual Toothbrush, Toothpaste, and Mouthwash

Oral Hygiene | Dental Plaque | Toothbrushing

Italy

Clinical Trials Sponsored by ADIR, a Servier Group company

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations